If you have been reading about lyophilized and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-07-31. Numbers and descriptions here follow the published literature rather than marketing material.
Measuring peptide exposure inside the brain is technically difficult. Selank is degraded rapidly in plasma, and assays must separate intact peptide from fragments, which favors targeted mass spectrometry over immunoassays alone. Reported half-lives are short, on the order of minutes, so effects observed hours later are attributed to downstream signaling rather than to the parent compound. Blood-brain barrier permeability is debated and rarely quantified directly. Gaps include absent dose-response characterization, inconsistent reporting of purity, and almost no pharmacokinetic data from human participants.
Selank is studied chiefly as an animal-model anxiolytic with proposed secondary effects on memory and immune signaling. Reported mechanisms include modulation of the GABA-A receptor complex, inhibition of enkephalin-degrading enzymes, and shifts in monoamine turnover within limbic structures. Some experiments describe increased expression of brain-derived neurotrophic factor in the hippocampus after repeated dosing. No single molecular target has been confirmed, and the peptide does not bind any receptor with the selectivity typical of a conventional small-molecule drug. Mechanism therefore remains a set of hypotheses rather than an established pathway.
Peptide bonds in selank are susceptible to hydrolysis under strongly acidic or basic conditions, and the terminal proline residues are vulnerable to exopeptidase activity in biological samples. Lyophilized powder stored dry at -20 °C typically remains stable for extended periods, whereas aqueous solutions degrade faster and may lose measurable purity within days to weeks depending on pH, temperature, and microbial load. Repeated freeze-thaw cycles promote aggregation and adsorption to container surfaces. For analytical work, solutions are usually prepared fresh, kept cold, and used within a single working day.
Handling follows standard practice for research peptides. Material is weighed in a low-humidity environment because the powder absorbs atmospheric moisture. Purity is reported as the percentage area of the main peak in a chromatogram, with specifications commonly set at 95 percent or higher; values below that threshold indicate the presence of truncated or modified species. Residual trifluoroacetate from purification is often present and may affect mass balance. Certificates of analysis should state the analytical method, the column and gradient used, and the lot-specific retention time so that results can be compared across suppliers.
Identity and purity of selank are established with reversed-phase high-performance liquid chromatography coupled to mass spectrometry. The peptide elutes from C18 columns with acetonitrile gradients in water containing trifluoroacetic acid or formic acid, and detection is usually performed by ultraviolet absorbance near 214 nm. Electrospray ionization in positive mode gives a doubly protonated ion near m/z 377, consistent with a mass of about 752 Da. Amino acid analysis or tandem mass spectrometry of fragment ions confirms the sequence. Because the molecule has no aromatic residues, it lacks a usable 280 nm chromophore, so low-wavelength detection or mass spectrometry is required.
| Property | Value | Notes |
|---|---|---|
| Principal proposed target | GABA-A receptor complex | Hypothesis derived mainly from animal pharmacology |
| Common behavioral assay | Elevated plus maze | Rodent test for anxiety-like behavior |
| Reported molecular marker | Hippocampal BDNF expression | Measured by immunoassay or mRNA quantification |
| Typical dosing route | Intranasal | Chosen to reduce first-pass metabolism |
| Reported plasma half-life | Minutes | Based on limited peptide stability data |
Characterization of Selank in a laboratory setting relies on standard peptide methods. Reverse-phase high-performance liquid chromatography separates the target from related impurities and provides a purity figure, commonly reported as 95 percent or higher. Mass spectrometry, typically electrospray ionization or matrix-assisted laser desorption, confirms the molecular mass and helps detect truncation or modification. Amino acid analysis can verify composition when a sequence-level check is needed. These techniques together establish identity and purity for a given lot.
Lyophilized Selank, the dry powder form, is generally stored frozen at minus 20 degrees Celsius or colder for long-term keeping. The solid is hygroscopic and should stay sealed, dry, and protected from light. Once dissolved, the peptide is less stable and is usually held refrigerated at 2 to 8 degrees Celsius for short periods. Repeated freezing and thawing is avoided because it can promote aggregation and loss of activity. Buffers and pH choice also affect how long a solution remains usable.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. Its four N-terminal residues reproduce tuftsin, a tetrapeptide fragment of the immunoglobulin heavy chain, while the C-terminal Pro-Gly-Pro extension is a synthetic addition. The peptide has a molecular mass near 752 daltons and carries a net positive charge at physiological pH because of the arginine and lysine side chains. Published indexes list it under the name Selank and the sequence abbreviation TKPRPGP. Solid-phase peptide synthesis is the standard production route for research quantities.
Development took place at the Institute of Molecular Genetics of the Russian Academy of Sciences, where a series of short peptides were designed in the 1980s and 1990s. Selank was selected from variants of tuftsin that showed resistance to plasma peptidases. Russian regulatory approval covers it as an anxiolytic agent given intranasally. Outside that market the compound is normally handled as a research chemical rather than a medicine, and no widely recognised international pharmacopoeial monograph exists. The name Selank is a coined trade designation rather than a systematic chemical name.
Enzymatic stability motivates the extra three residues at the carboxyl end. Native tuftsin is cleaved quickly by circulating aminopeptidases and carboxypeptidases, which limits its duration of action and its usefulness as a tool compound. Extending the chain with proline-rich segments is a common design tactic because proline constrains the backbone and slows proteolysis. The same Pro-Gly-Pro motif appears in other Russian-developed peptides of the era. Whether the full seven-residue chain is required for activity, or whether it acts mainly as a prodrug releasing tuftsin, remains unresolved.
Selank is a synthetic heptapeptide developed in Russia during the 1990s. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences designed it as a stabilized analog of tuftsin, a naturally occurring immunomodulatory tetrapeptide. The compound has been studied primarily for its reported anxiolytic and nootropic effects. It remains largely unknown in Western pharmacology and is not approved as a medicine by major regulators such as the FDA or the EMA.
The primary structure of Selank is Thr-Lys-Pro-Arg-Pro-Gly-Pro, corresponding to the molecular formula C33H57N11O9 and a monoisotopic mass of roughly 751.9 daltons. The N-terminal threonine and the arginine residue in the fourth position are shared with tuftsin, which carries the sequence Thr-Lys-Pro-Arg. The three additional residues at the C-terminus, Pro-Gly-Pro, extend the chain and are associated with greater resistance to enzymatic degradation. This extension also separates Selank from the shorter parent peptide.
Capillary electrophoresis (CE) is a family of electrokinetic separation methods performed in submillimeter diameter capillaries and in micro- and nanofluidic channels. Very often, CE refers to capillary zone electrophoresis (CZE), but other electrophoretic techniques including capillary gel electrophoresis (CGE), capillary isoelectric focusing (CIEF), capillary isotachophoresis and micellar electrokinetic chromatography (MEKC) belong also to this class of methods. In CE methods, analytes migrate through electrolyte solutions under the influence of an electric field. Analytes can be separated according to ionic mobility and/or partitioning into an alternate phase via non-covalent interactions. Additionally, analytes may be concentrated or "focused" by means of gradients in conductivity and pH.
== Structure == Sucrose is a disaccharide formed from condensation of glucose and fructose to produce α-D-glucopyranosyl-(1→2)-β-D-fructofuranoside. Sucrose has 8 hydroxyl groups which can be reacted with fatty acid esters to produce sucrose esters. Among the 8 hydroxyl groups on sucrose, three (C6, C1', and C6') are primary while the others (C2, C3, C4, C3', and C4') are secondary. (The numbers 1-6 indicate the position of the carbons on glucose while the numbers 1'-6' indicate the position of the carbons on fructose.) The three primary hydroxyl groups are more reactive due to lower steric hindrance, so they react with fatty acids first, resulting in a sucrose mono-, di-, or triester. Typical saturated fatty acids that are used to produce sucrose esters are lauric acid, myristic acid, palmitic acid, stearic acid and behenic acid, and typical unsaturated fatty acids are oleic acid and erucic acid.
High Voltage Engineering Corporation accelerators originated with the electrostatic generator designed by MIT physicist Robert J. Van de Graaff. In an effort to split the atom, Van de Graaff devised a electrostatic method to accelerate and direct charged particles at high voltages. While constructing a high-voltage prototype accelerator in the early 1930s, Van de Graaff patented several technologies that would form part of the future company's technology base. MIT professor John G. Trump, an apprentice of Van de Graaff, focused on making the generators useful for cancer radiotherapy. In the 1930s, few hospitals could afford radium sources, available x-ray sources were insufficiently powerful, and both methods damaged healthy tissues. Trump proposed that the unlimited, controllable beam output of Van de Graaff devices could make treatment affordable and safer. He built a series of compact "supervoltage" (>1-megavolt) x-ray generators for local cancer hospitals and secured further patents for the smaller generators. Returning from his World War II leave, Trump received requests from several British hospitals for new cancer generators and decided a company could better fulfill further orders. He recruited Van de Graaff to serve as co-founder and chief scientist. Neither professor wished to leave MIT, so Trump brought in British physicist Denis M. Robinson as a third co-founder and president. In 1946, Trump approached his wartime colleague, MIT President Karl Compton, about supporting the venture.
Central nervous system: headache (7%), dizziness (2%) Respiratory: upper respiratory tract infection (2%), cough (1%) Gastrointestinal: abdominal pain (5%), diarrhea (4%), nausea (4%), vomiting (3%), flatulence (3%), acid regurgitation (2%), constipation (2%) Neuromuscular and skeletal: back pain (1%), weakness (1%) Dermatologic: rash (2%) Other concerns related to adverse effects are:
Sources: en.wikipedia.org
==== Iron import ==== Most cell types take up iron primarily through receptor-mediated endocytosis via transferrin receptor 1 (TFR1), transferrin receptor 2 (TFR2) and GAPDH. TFR1 has a 30-fold higher affinity for transferrin-bound iron than TFR2 and thus is the main player in this process. The higher order multifunctional glycolytic enzyme glyceraldehyde-3-phosphate dehydrogenase (GAPDH) also acts as a transferrin receptor. Transferrin-bound ferric iron is recognized by these transferrin receptors, triggering a conformational change that causes endocytosis. Iron then enters the cytoplasm from the endosome via importer DMT1 after being reduced to its ferrous state by a STEAP family reductase. Alternatively, iron can enter the cell directly via plasma membrane divalent cation importers such as DMT1 and ZIP14 (Zrt-Irt-like protein 14). Again, iron enters the cytoplasm in the ferrous state after being reduced in the extracellular space by a reductase such as STEAP2, STEAP3 (in red blood cells), Dcytb (in enterocytes) and SDR2.
Chancellor Rachel Reeves conducts a spending review in which she limits winter fuel payments to pensioners receiving pension credit (affecting around 10 million people), and announces the cancellation of several infrastructure projects. Reeves argues she has had to make "necessary and urgent decisions" because of an "unfunded" and "undisclosed" overspending of £21.9bn by the previous government. The shadow chancellor, Jeremy Hunt, disagrees with Reeves, saying that when his party was in power there were no hidden overspends and that the government had been open about public finances. Hunt says Reeves misled the country knowing "taxes will have to go up, and she chose not to tell us". He predicts that her first Budget will be the "biggest betrayal in history by a new chancellor". The new Labour government scraps the controversial proposed Stonehenge road tunnel. 2024 Summer Olympics: The first gold medal for Team GB is won by Laura Collett in the final round of show jumping. Tom Pidcock wins a second in mountain biking later in the day. A judge issues an arrest warrant for Tommy Robinson after he left the UK via Eurotunnel on the eve of a major court case against him. Former BBC newsreader Huw Edwards is charged with making indecent images of children. The High Court rules that the previous government's use of emergency legislation to ban puberty blockers is lawful. 30 July 2024 Southport stabbing: The three young girls killed in the attack are named as Bebe King, aged 6; Elsie Dot Stancombe, aged 7; and Alice Dasilva Aguiar, aged 9.
Actin, alpha 1 Actinin, alpha 1 Adaptor-related protein complex 2, alpha 1 Aldehyde dehydrogenase 3 family, member A1 Aldehyde dehydrogenase 4 family, member A1 Aldehyde dehydrogenase 5 family, member A1 Aldehyde dehydrogenase 6 family, member A1 Aldehyde dehydrogenase 9 family, member A1 Aldehyde dehydrogenase 18 family, member A1 Aldo-keto reductase family 1, member A1 Alpha-1-microglobulin/bikunin precursor Apolipoprotein A1 and ApoA-1 Milano ATPase, H+ transporting, lysosomal V0 subunit a1 ATPase, Na+/K+ transporting, alpha 1 ATP synthase, H+ transporting, mitochondrial F1 complex, alpha 1 BCL2-related protein A1 Butyrophilin, subfamily 1, member A1 Butyrophilin, subfamily 3, member A1 Capping protein (actin filament) muscle Z-line, alpha 1 Carboxypeptidase A1 Casein kinase 1, alpha 1 Casein kinase 2, alpha 1 Catenin (cadherin-associated protein), alpha 1 Centaurin, alpha 1 Cholinergic receptor, nicotinic, alpha 1 Coagulation factor XIII, A1 polypeptide collagen, type I, alpha 1 collagen, type II, alpha 1 Collagen, type III, alpha 1 Collagen, type IV, alpha 1 Collagen, type V, alpha 1 Collagen, type VI, alpha 1 Collagen, type VII, alpha 1 Collagen, type VIII, alpha 1 Collagen, type IX, alpha 1 Collagen, type X, alpha 1 Collagen, type XI, alpha 1 Collagen, type XII, alpha 1 Collagen, type XIII, alpha 1 Collagen, type XIV, alpha 1 Collagen, type XV, alpha 1 Collagen, type XVI, alpha 1 Collagen, type XVII, alpha 1 Collagen, type XVIII, alpha 1 Collagen, type XIX, alpha 1 Collagen, type XXV, alpha 1 Collagen, type XXVII, alpha 1 Crystallin, beta A1 Cyclic nucleotide-gated channel alpha 1 Cyclin A1 Cytochrome P450, family 1, member A1 Defensin, alpha 1 Dystrophin-associated protein A1 Ephrin A1 Eukaryotic translation elongation factor 1 alpha 1 Family with sequence similarity 13, member A1 Family with sequence similarity 19 (chemokine (C-C motif)-like), member A1 Gamma-aminobutyric acid (GABA) A receptor, alpha 1 Gap junction protein, alpha 1 GDNF family receptor alpha 1 Glutathione S-transferase A1 Glycine receptor, alpha 1 Heat shock protein 90kDa alpha (cytosolic), member A1 Hemoglobin, alpha 1 Heterogeneous nuclear ribonucleoprotein A1 Homeobox A1 Immunoglobulin heavy constant alpha 1 Importin alpha 1 Interferon, alpha 1 Interleukin 13 receptor, alpha 1 Karyopherin alpha 1 Laminin, alpha 1 Major histocompatibility complex, class II, DP alpha 1 Major histocompatibility complex, class II, DQ alpha 1 Myosin light chain A1, an actin-binding protein NADH dehydrogenase (ubiquinone), alpha 1 Nucleolar protein, member A1 PCDHA4 Phospholipase A1 Phosphorylase kinase, alpha 1 Plexin A1 Polymerase (DNA directed), alpha 1 Potassium large conductance calcium-activated channel, subfamily M, alpha 1 Proteasome (prosome, macropain) subunit, alpha 1 Protein kinase, AMP-activated, alpha 1 Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1 Protocadherin alpha 1 Pulmonary surfactant-associated protein A1 Pyruvate dehydrogenase (lipoamide) alpha 1 RNA binding motif protein, Y-linked, family 1, member A1 Replication protein A1 S100 calcium binding protein A1 Sec61 alpha 1 Serum amyloid A1 Solute carrier family 35 (CMP-sialic acid transporter), member A1 Spectrin, alpha 1 Sperm protein associated with the nucleus, X-linked, family member A1 Syntrophin, alpha 1 Transient receptor potential cation channel, member A1 UDP glucuronosyltransferase 1 family, polypeptide A1 Urea Transporter A1 a gene found in the maize encoding for the dihydroflavonol 4-reductase (reducing dihydroflavonols into flavan-4-ols) in the phlobaphene metabolic pathway proteins
Sources: en.wikipedia.org
By contrast, in IBM v Commission the Court of Justice held that a letter from the commission to IBM that it would sue IBM for abusing a dominant position contrary to competition was not a reviewable act, but just a preliminary statement of intent to act. In any case, if a reviewable act of an EU institution is not found compatible with the law, under article 264, it will be declared void.
== Later life and FOP progression == Unaware of the consequences of surgery on an FOP patient, the physician admitted Eastlack for hip surgery in 1941 which caused further physical restriction. Over time Eastlack became more and more immobilized as more joints became fused and newly formed sheets or strings of bone calcified his limbs. In 1944, he was readmitted for a study which confirmed that the calcified smooth muscles, tendons, and ligaments had indeed become mature bone. The ossification along his vertebrae and other anatomical parts that Eastlack would suffer in the next 29 years ultimately fused him into a permanently bowed position. Eastlack's case of FOP progressed at a more rapid rate due to the number of intrusive surgeries he underwent. In 1948, at the age of 15, his jaw had become fused so he could no longer eat solid food and had to speak through clenched teeth. At a young age, he faced difficulty sitting down, as well. His hips were one of the first anatomical parts to become immobilized due to heterotopic ossification. Soon, bone formed across his upper arms and extended onto his sternum, tying his arms to his breast. Sheets of bone spread along his back and ribbons of bone extended from there to his skull, inhibiting proper head movement. The new bone growths throughout the years also caused juts of bone to form on his pelvis and thighs, and it caused both of his feet to become clubbed. One year he accidentally bumped his buttocks into a radiator, and this resulted in a bruise wherein the smooth tissue was destroyed and gave way to newly formed bone.
=== The origin of plasmapheresis === Dr. José Antonio Grifols Lucas, a scientist from Vilanova i la Geltrú, Spain, founded Laboratorios Grifols in 1940. Dr. Grifols pioneered a first-of-its-kind technique called plasmapheresis, where a donor's red blood cells would be returned to the donor's body almost immediately after the separation of the blood plasma. This technique is still in practice today, almost 80 years later. In 1945, Dr. Grifols opened the world's first plasma donation center.
Sources: en.wikipedia.org
Intranasal administration predominates in both animal and human research because it avoids hepatic first-pass metabolism. Injectable and intraperitoneal routes appear in animal work mainly for comparison.
Behavioral endpoints include time spent in open arms of the elevated plus maze and avoidance latencies. Biochemical endpoints include BDNF concentration, cytokine levels, and monoamine metabolite ratios in brain tissue.
Most published studies are small, originate from a limited number of laboratories, and lack independent replication. Dose-response relationships, measured brain exposure, and long-term outcomes are not well characterized.
Identity is confirmed by matching the retention time in reversed-phase chromatography against a reference standard and by measuring the molecular mass with mass spectrometry. Tandem mass spectrometry or amino acid analysis can verify the sequence of the seven residues. Because the peptide contains no aromatic amino acids, detection at 280 nm is not useful.